Sunteți pe pagina 1din 10

Vancomycin-Resistant Enterococcus faecium Infections Pipeline Review, H2 2015 Is Released

Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Review, H2 2015 Summary Global

Markets Direct s, Vancomycin-Resistant Enterococcus Faecium Infections - Pipeline Review, H2 2015 ,
provides an overview of the Vancomycin-Resistant Enterococcus Faecium Infections s therapeutic
pipeline. This report provides comprehensive information on the therapeutic development for
Vancomycin-Resistant Enterococcus Faecium Infections, complete with comparative analysis at various
stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type, along with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for Vancomycin-Resistant Enterococcus
Faecium Infections and special features on late-stage and discontinued projects. Global Markets Directs
report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000
indications. The report is built using data and information sourced from Global Markets Directs
proprietary databases, Company/University websites, SEC filings, investor presentations and featured
press releases from company/university sites and industry-specific third party sources, put together by
Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation
following a stringent set of processes that ensures that all the profiles are updated with the latest set of
information. Additionally, processes including live news & deals tracking, browser based alert-box and
clinical trials registries tracking ensure that the most recent developments are captured on a real time
basis. The report enhances decision making capabilities and help to create effective counter strategies
to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to
produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed
or altered based on the availability and relevance of data for the indicated disease. Scope - The report
provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Enterococcus Faecium
Infections - The report reviews key pipeline products under drug profile section which includes, product
description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Vancomycin-Resistant
Enterococcus Faecium Infections and enlists all their major and minor projects - The report summarizes
all the dormant and discontinued pipeline projects - A review of the Vancomycin-Resistant Enterococcus
Faecium Infections products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources - Pipeline products coverage
based on various stages of development ranging from pre-registration till discovery and undisclosed
stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of
the Vancomycin-Resistant Enterococcus Faecium Infections pipeline on the basis of target, MoA, route
of administration and molecule type - Latest news and deals relating related to pipeline products
Reasons to buy - Provides strategically significant competitor information, analysis, and insights to
formulate effective R&D development strategies - Identify emerging players with potentially strong
product portfolio and create effective counter-strategies to gain competitive advantage - Develop
strategic initiatives by understanding the focus areas of leading companies - Identify and understand
important and diverse types of therapeutics under development for Vancomycin-Resistant Enterococcus
Faecium Infections - Plan mergers and acquisitions effectively by identifying key players of the most
promising pipeline - Devise corrective measures for pipeline projects by understanding Vancomycin1

Resistant Enterococcus Faecium Infections pipeline depth and focus of Indication therapeutics - Develop
and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope - Modify the therapeutic
portfolio by identifying discontinued projects and understanding the factors that drove them from
with TOC @


To Get Sample Copy of Report visit @

Table of Contents

Introduction 9
Global Markets Direct Report Coverage 9
Vancomycin-Resistant Enterococcus faecium Infections Overview 10
Therapeutics Development 11
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Overview 11
Pipeline Products for Vancomycin-Resistant Enterococcus faecium Infections - Comparative Analysis 12
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Development by
Companies 13
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics under Investigation by
Universities/Institutes 15
Vancomycin-Resistant Enterococcus faecium Infections - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Vancomycin-Resistant Enterococcus faecium Infections - Products under Development by Companies 19
Vancomycin-Resistant Enterococcus
Universities/Institutes 21







Vancomycin-Resistant Enterococcus faecium Infections - Companies Involved in Therapeutics

Development 22
Alchemia Limited 22

Alvogen Korea 23
Aphios Corporation 24
BioSource Pharm, Inc. 25
Cellceutix Corporation 26
Helix BioMedix, Inc. 27
Hsiri Therapeutics, LLC 28
LegoChem Biosciences, Inc 29
Lytix Biopharma AS 30
MGB Biopharma Limited 31
Microbiotix, Inc. 32
MicuRx Pharmaceuticals, Inc. 33
NovaBay Pharmaceuticals, Inc. 34
NovoBiotic Pharmaceuticals, LLC 35
Oragenics, Inc. 36
Sealife PHARMA GMBH 37
Sentinella Pharmaceuticals, Inc. 38
TAXIS Pharmaceuticals, Inc. 39
Wockhardt Limited 40
Vancomycin-Resistant Enterococcus faecium Infections - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Target 42
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
auriclosene - Drug Profile 50
Product Description 50

Mechanism of Action 50
R&D Progress 50
brilacidin tetrahydrochloride - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BSPC-728 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
chrysophaentin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
closthioamide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Epimerox - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
HB-1345 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58

HT-01 - Drug Profile 59

Product Description 59
Mechanism of Action 59
R&D Progress 59
HT-02 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
IBN-1 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
LCB-010371 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LCB-010699 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
LTX-109 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Marinus - Drug Profile 68
Product Description 68
Mechanism of Action 68

R&D Progress 68
MBX-1162 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MGBBP-3 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
MRX-I - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MRX-IV - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
MU-1140 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
NAI-107 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
NAI-603 - Drug Profile 77

Product Description 77
Mechanism of Action 77
R&D Progress 77
SLP-0904 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
SLP-0905 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecule to Inhibit Glycosyltransferase for Bacterial Infection - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
Small Molecules for MRSA and Vancomycin-Resistant Enterococcus Faecium Infections - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Small Molecules to Inhibit FtsZ Protein for MRSA and VRE Infections - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83

SP-2078 - Drug Profile 84

Product Description 84
Mechanism of Action 84
R&D Progress 84
Teixobactin - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
WCK-4086 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Vancomycin-Resistant Enterococcus faecium Infections - Recent Pipeline Updates 89
Vancomycin-Resistant Enterococcus faecium Infections - Dormant Projects 104
Vancomycin-Resistant Enterococcus faecium Infections - Discontinued Products 105
Vancomycin-Resistant Enterococcus faecium Infections - Product Development Milestones 106
Featured News & Press Releases 106
Feb 25, 2015: MicuRx Initiates U.S. Phase 2 Clinical Trial for Novel Antibiotic MRX-I 106
Aug 26, 2013: Oragenics Collaboration Demonstrates Initial Success in the Second Phase of Lantibiotics
Project 106
Feb 12, 2013: Oragenics-Intrexon Collaboration Announces Significant Progress towards Commercial
Production of Lead Lantibiotic MU1140 107
Sep 12, 2012: NovaBay Pharma Announces Data from New Study Demonstrating Chemical Impact of Nchlorotaurine And NVC-422 On Bacterial Toxins 107
May 23, 2012: MicuRx Announces Issuance Of US Patent For Next-Generation Antibacterial Agent 108
Apr 23, 2012: MicuRx Completes Phase I Trial for MRX-I 108
Appendix 109
Methodology 109

Coverage 109
Secondary Research 109
Primary Research 109
Expert Panel Validation 109
Contact Us 109
Disclaimer 110

Read More
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading
market research information aggregator and marketing research consulting firm. We conduct both
primary and secondary research. Our work does not end with research it is also involved in distributing
reports for different companies . We provide actionable recommendations and provide our expertise for
business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and
discovery, and then be their guide in the implementation of changes that will make a difference to their
bottom line.
iData Insights
Tel: 1-866-237-2965
About iData Insights
We work around the clock until our clients are completely satisfied with their promised results. It is our
mission to provide timely services coupled with acute client care to create a long-lasting relationship
with you. We deliver on our promise to provide results that are essential to the success of your
company. We believe that by doing so, we will earn the trust of our clients for future projects